Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Medtech - Caught on Camera

From drought to demand: Biotech IPOs roar back with Kailera and Alamar

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks up most venture dollars.

Fortune

Stryker Cyberattack Sparks Health Sector Alert as Iran-Linked Hackers Target Medtech Firm Serving 150M Patients

Learn about the impact on global healthcare operations and the urgent measures being taken to protect patient care and MedTech security

International Business Times UK

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

Why Requirements Management Is Critical in Regulated Device Development

In the development of regulated medical devices, adherence to stringent regulatory requirements is not optional but a foundational necessity. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others around the world enforce strict guidelines to ensure the safety, efficacy, and reliability…

inkl

Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

MarketBeat

AngioDynamics Eyes Growth Despite Tariffs

AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What's Fueling The Momentum In AngioDynamics Stock?

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.

Benzinga

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Barchart

3 Dividend Stocks to Hold Through Market Volatility This Fall

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

MarketBeat

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

JNJ Stock Surge Signals Confidence in New Growth Path

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

MarketBeat

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Barchart

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

Benzinga

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

MarketBeat

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

Barchart

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

Barchart

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Barchart

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

Dr. LEVY Switzerland The ThermoGlow Pro review: salon-quality home facials for firmer, clearer, younger-looking skin

Get your glow on with the biohacking skincare device that cleanses, purifies and revitalises

Barchart

3 MedTech Stocks to Grab Now for a Strong 2025

This article highlights three MedTech stocks poised for growth in 2025

Benzinga

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.